Search
Results for “Cancer Genomics”
6 matches across companies, investors, executives, technologies, markets, research and news.
Technologies
- Cancer GenomicsComprehensive genomic profiling, minimal residual disease testing and tumour-informed sequencing.
Research
- Cancer Genomics OutlookComprehensive genomic profiling, minimal residual disease and the competitive position of the vertically integrated providers.
News
- Tempus acquires Personalis in $1.5bn deal, deepening push into cancer genomicsThe AI-diagnostics firm absorbs its oncology genomics partner three years after their initial collaboration — and sets up a direct contest with Foundation Medicine for NHS pathology contracts. Full deal terms, adviser detail and competitive landscape analysis in the intelligence database.
Companies
- PersonalisMinimal-residual-disease and tumour-informed sequencing company, being acquired by Tempus in a $1.5bn transaction.
- Foundation MedicineComprehensive genomic profiling provider owned by Roche, and the principal competitor for NHS pathology network contracts.
Diseases
- Lung CancerLung cancer screening, targeted therapy and genomic profiling.